Recent advances on smart glycoconjugate vaccines in infections and cancer
Аутори
Anderluh, MarkoBerti, Francesco
Bzducha-Wróbel, Anna
Chiodo, Fabrizio
Colombo, Cinzia
Compostella, Federica
Durlik, Katarzyna
Ferhati, Xhenti
Holmdahl, Rikard
Jovanović, Dragana J.
Kaca, Wieslaw
Lay, Luigi
Marinović-Cincović, Milena
Marradi, Marco
Ozil, Musa
Polito, Laura
Reina, Josè Juan
Reis, Celso A.
Sackstein, Robert
Silipo, Alba
Švajger, Urban
Vaněk, Ondřej
Yamamoto, Fumiichiro
Richichi, Barbara
van Vliet, Sandra J.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally s...erve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.
Кључне речи:
cancer / glycosylation / immune system / infection / vaccinationИзвор:
The FEBS Journal, 2021, 289, 4251-4303Финансирање / пројекти:
- COST [CA18103]
- Ministry of Education, Youth & Sports - Czech Republic [CA18103, LTC20078]
DOI: 10.1111/febs.15909
ISSN: 1742-4658
PubMed: 33934527
WoS: 000656594400001
Scopus: 2-s2.0-85107309134
Колекције
Институција/група
VinčaTY - JOUR AU - Anderluh, Marko AU - Berti, Francesco AU - Bzducha-Wróbel, Anna AU - Chiodo, Fabrizio AU - Colombo, Cinzia AU - Compostella, Federica AU - Durlik, Katarzyna AU - Ferhati, Xhenti AU - Holmdahl, Rikard AU - Jovanović, Dragana J. AU - Kaca, Wieslaw AU - Lay, Luigi AU - Marinović-Cincović, Milena AU - Marradi, Marco AU - Ozil, Musa AU - Polito, Laura AU - Reina, Josè Juan AU - Reis, Celso A. AU - Sackstein, Robert AU - Silipo, Alba AU - Švajger, Urban AU - Vaněk, Ondřej AU - Yamamoto, Fumiichiro AU - Richichi, Barbara AU - van Vliet, Sandra J. PY - 2021 UR - https://vinar.vin.bg.ac.rs/handle/123456789/9834 AB - Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy. T2 - The FEBS Journal T1 - Recent advances on smart glycoconjugate vaccines in infections and cancer VL - 289 SP - 4251 EP - 4303 DO - 10.1111/febs.15909 ER -
@article{ author = "Anderluh, Marko and Berti, Francesco and Bzducha-Wróbel, Anna and Chiodo, Fabrizio and Colombo, Cinzia and Compostella, Federica and Durlik, Katarzyna and Ferhati, Xhenti and Holmdahl, Rikard and Jovanović, Dragana J. and Kaca, Wieslaw and Lay, Luigi and Marinović-Cincović, Milena and Marradi, Marco and Ozil, Musa and Polito, Laura and Reina, Josè Juan and Reis, Celso A. and Sackstein, Robert and Silipo, Alba and Švajger, Urban and Vaněk, Ondřej and Yamamoto, Fumiichiro and Richichi, Barbara and van Vliet, Sandra J.", year = "2021", abstract = "Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.", journal = "The FEBS Journal", title = "Recent advances on smart glycoconjugate vaccines in infections and cancer", volume = "289", pages = "4251-4303", doi = "10.1111/febs.15909" }
Anderluh, M., Berti, F., Bzducha-Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., Kaca, W., Lay, L., Marinović-Cincović, M., Marradi, M., Ozil, M., Polito, L., Reina, J. J., Reis, C. A., Sackstein, R., Silipo, A., Švajger, U., Vaněk, O., Yamamoto, F., Richichi, B.,& van Vliet, S. J.. (2021). Recent advances on smart glycoconjugate vaccines in infections and cancer. in The FEBS Journal, 289, 4251-4303. https://doi.org/10.1111/febs.15909
Anderluh M, Berti F, Bzducha-Wróbel A, Chiodo F, Colombo C, Compostella F, Durlik K, Ferhati X, Holmdahl R, Jovanović DJ, Kaca W, Lay L, Marinović-Cincović M, Marradi M, Ozil M, Polito L, Reina JJ, Reis CA, Sackstein R, Silipo A, Švajger U, Vaněk O, Yamamoto F, Richichi B, van Vliet SJ. Recent advances on smart glycoconjugate vaccines in infections and cancer. in The FEBS Journal. 2021;289:4251-4303. doi:10.1111/febs.15909 .
Anderluh, Marko, Berti, Francesco, Bzducha-Wróbel, Anna, Chiodo, Fabrizio, Colombo, Cinzia, Compostella, Federica, Durlik, Katarzyna, Ferhati, Xhenti, Holmdahl, Rikard, Jovanović, Dragana J., Kaca, Wieslaw, Lay, Luigi, Marinović-Cincović, Milena, Marradi, Marco, Ozil, Musa, Polito, Laura, Reina, Josè Juan, Reis, Celso A., Sackstein, Robert, Silipo, Alba, Švajger, Urban, Vaněk, Ondřej, Yamamoto, Fumiichiro, Richichi, Barbara, van Vliet, Sandra J., "Recent advances on smart glycoconjugate vaccines in infections and cancer" in The FEBS Journal, 289 (2021):4251-4303, https://doi.org/10.1111/febs.15909 . .